Yes, and just one more all important step to claim Precision Medicine is selecting patients based on the characteristics/biomarkers with the best response.
As per slide 5 of the 2021 Dec Corp Presentation, the probability of succes increases with: Patient selection biomarkers, Higher therapeutic response and Lower variability in the target population.
Anavex are doing work on identifying biomarkers and we will likely see new/additional biomarkers beyond the SIGMAR1 wt and variant gene expression from the analysis of the current trials data incl. the PDD OLE study and gut microbiome.
Subsequently, imo we are likely to see P3 trials selecting patients based on one or more biomarkers. Getting this right in preparation for the upcoming potentially pivotal trials in PD, PDD, Fragile-X and undisclosed indication(s) probably takes time - you don't want to precisely select for the wrong subgroup of patients!
By then the Precision Medicine/Therapeutics approach will become reality. For now Anavex have rightly toned down the website wording and focusing on biomarkers.
News 
Market Data 
Discover 
